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High concentrations of pituitary adenylate cyclase-activating polypeptide (PACAP) nerve ﬁbers are present in the central nucleus
of amygdala (CeA), a brain region implicated in the control of fear-related behavior. This study evaluated PACAPergic modulation
of fear responses at the CeA in male Sprague-Dawley rats. PACAP (50–100pmol) microinfusion via intra-CeA cannulae produced
increases in immobility and time the rats spent withdrawn into a corner opposite to the electriﬁed probe compared to controls
in the shock-probe fear/defensive burying test. Shock-probe burying and exploration, numbers of shocks received, locomotion
distance, and velocity were all reduced by intra-CeA PACAP injection. Further, intra-CeA PACAP eﬀects were manifested only
when the animals were challenged by shock, as intra-CeA PACAP injections did not cause signiﬁcant changes in the behaviors
of unshocked rats. Thus, intra-CeA administration of PACAP produces a distinct reorganization of stress-coping behaviors from
active (burying) to passive modes, such as withdrawal and immobility. These ﬁndings are potentially signiﬁcant toward enhancing
our understanding of the involvement of PACAP and the CeA in the neural basis of fear and anxiety.
Copyright © 2007 Gabor Legradi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Pituitary adenylate cyclase-activating polypeptide (PACAP),
a member of the secretin/glucagon/vasoactive intestinal pep-
tide superfamily (Arimura and Shioda [1]), is a pleiotropic
moleculewithremarkablecentralactionsonneuroendocrine
and behavioral systems. Intracerebroventricular (icv) or in-
trahypothalamic PACAP injection results in a signiﬁcant and
long-lasting reduction of food intake (Morley et al. [2];
Chance et al. [3]), elevated plasma vasopressin, mean arte-
rial blood pressure levels, and induces c-fos and vasopressin
gene expression in the hypothalamus (Murase et al. [4]; No-
mura et al. [5]). A marked increase in steady-state levels of
CRH gene expression in the hypothalamic paraventricular
nucleus(PVN)wasdetectedaftericvPACAPinjection,which
was blocked by coadministration of a selective PACAP re-
ceptor antagonist (Grinevich et al. [6]). PACAP nerve ﬁbers
heavilyinnervatethemajorityofcorticotropin-releasinghor-
mone (CRH) neurons in the PVN (Legradi et al. [7]) and icv
PACAP administration under stress-free conditions in freely
moving rats increased corticosterone levels and acutely acti-
vatedPVNCRHneurons(Agarwaletal.[8]),mimickingim-
portant aspects of stress activation. Our group reported that
PACAPinfusedintothePVNincreasedself-groomingbehav-
ior and suppressed ongoing exploratory activity (Norrholm
et al. [9]). These data support the view that PACAP acts as an
excitatory neuropeptide, recapitulating previously demon-
strated behavioral eﬀects of electrical and neurochemical
PVN activation (Van Erp et al. [10]; Monnikes et al. [11]).
Evaluation of time course of PACAP-induced behaviors indi-
cated a cumulative eﬀect of intra-PVN PACAP administra-
tion and restraint stress, thereby supporting our hypothesis2 Neural Plasticity
that PACAP ampliﬁes the eﬀects of stress on behavior (Nor-
r h o l me ta l .[ 9]).
The inﬂuence of PACAP on brain function has also been
investigated in learning and memory studies. For example,
icv injection of PACAP facilitated the learning, as well as
retrieval, of the passive avoidance response (Telegdy and
Kokavszky [12]). This ﬁnding further highlighted the poten-
tial contribution of PACAP to neurobehavioral responses to
aversive or threatening stimuli, but its action site could not
be determined from their study, further necessitating spe-
ciﬁc anatomical pharmacologic identiﬁcation of PACAP tar-
getregions.Inadditiontotheneuroendocrineandgrooming
eﬀects mediated by the hypothalamus, PACAPergic mecha-
nisms in stress responsivity may be processed through the
amygdala. The amygdala is viewed as an interface between
sensory information and defensive behavioral output, such
as manifestations of fear or anxiety (Maren [13]; Davis [14];
LeDoux [15]). Whereas the lateral and basolateral nuclei
are responsible for forming the association between fearful
and neutral stimuli, perhaps through potentiation of synap-
tic transmission, the central nucleus (CeA) is implicated in
the behavioral and autonomic expressions of fear (LeDoux
[16];Davis[14]).Strikinglyhighdensitiesofnerveﬁbersim-
munoreactive for PACAP have been identiﬁed in the central-
extended amygdala that includes the central nucleus of the
amygdala (CeA) and the lateral part of the bed nucleus of the
stria terminalis(Koves et al. [17]; Kivipelto et al. [18]; Pig-
gins et al. [19]; Kozicz et al. [20]; Hannibal [21]). Likewise,
medium to high densities of speciﬁc PACAP receptor (PAC1-
R) expression were detected in CeA (Hashimoto et al. [22])
suggesting local physiologic role for the peptide.
The dense innervation of the amygdala by PACAP nerve
ﬁbers clearly indicates that this peptide can exert a strong,
butlargelyunknown,inﬂuenceonamygdaloidfunction.The
present study, therefore, was designed to explore PACAP’s
contribution to the regulation of fear behavior, speciﬁcally at
the level of the central nucleus of amygdala, using the shock-
probe fear test. This method was originally developed as the
defensive burying paradigm by Treit and coworkers (Treit
and Pinel [23]). Findings from Treit’s laboratory and others
have suggested that either an increased burying response or
increased withdrawal from the probe and immobility would
be interpreted as qualitatively diﬀerent expressions of fear
behaviors evoked in response to the electriﬁed shock probe.
These two basic modes of coping have been viewed as active
or passive, according to several investigators (Roozendaal et
al. [24] ;T r e i te ta l .[ 25]; Degroot et al. [26]; De Boer and
Koolhaas [27]) enabling the evaluation of aversive behaviors
by quantitative, as well as qualitative, criteria. Therefore, in
the current study we hypothesized that local administration
of PACAP into the central amygdala would exert a strong in-
ﬂuenceontheexpression ofcoping behaviorsinratsexposed
to the electriﬁed probe.
2. MATERIALS AND METHODS
2.1. Animalsandsurgery
MaleSprague-Dawleyrats(TaconicFarms,NY,USA),weigh-
ing 210–240 upon arrival, were used for the study (total
n = 58). Animals were pair-housed until cannula implanta-
tion surgery and then single-housed in polycarbonate cages
and maintained on a 12:12-hour light/dark cycle (lights on
at 0700 hours), with food and water available ad libitum.
Rats were handled daily for a week and habituated to the
environmental conditions in the testing room. All proce-
dures were carried out in accordance with the University of
South Florida Institutional Animal Care and Use Committee
guidelines regarding the care and use of experimental ani-
mals. After an initial 1-week acclimation and handling pe-
riod, rats were anesthetized with Ketamine (90mg/kg) and
Xylazine (10mg/kg) and a 24-gauge stainless steel guide can-
nula (Plastics One, Roanoke, Va, USA) was unilaterally im-
planted into the right central nucleus of amygdala under
stereotaxic control (coordinates: 2.4 to 2.6mm caudal to
bregma, 4.4 to 4.5mm lateral to the midline, and 5.5 to
5.6mm below the skull surface) through a burr hole in the
skull. Cannulae were secured to the skull with three stain-
less steel anchor screws and cranioplastic cement and tem-
porarilyoccludedwithadummycannula.Followingsurgery,
ketoprofen (5mg/kg) was injected subcutaneously to mini-
mizepost-surgicalpainandinﬂammation.Unilateralcannu-
lation of the right amygdala (Huston et al. [28]) was chosen
since this side, compared to the left amygdala, has greater in-
volvement in fear conditioning and anxiety responses (Baker
and Kim [29]) and unilateral manipulations are surgically
less invasive. Experiments were conducted 7–8 days post-
surgery and during the light period of the cycle (1000 and
1400 hours).
2.2. Shock-probefeartest
For four consecutive days before behavioral experimenta-
tion, rats were given mock injections by attaching the guide
cannula to an empty injection connector tubing for 2 min-
utesintheirhomecageandthenthetubingwasdisconnected
and the rats were exposed to the test chamber without the
shock probe for 20 minutes. During the pretest session (the
daybeforetheexperiment)individualratsweregivenamock
injection, and exposed to the test chamber in presence of an
unelectriﬁed shock probe for 20 minutes. Animal behavior
was recorded onto digital video ﬁles at these pretest sessions.
Rats were randomly assigned into either the control or
experimental groups prior to behavioral testing and infused
with artiﬁcial cerebrospinal ﬂuid (aCSF control) or PACAP
(PACAP38; American peptide company, Sunnyvale, Calif,
USA) using a BAS bee syringe pump system (West Lafayette,
Ind, USA) connected to a 31-gauge internal cannula (Plas-
tics one, outer diameter 0.25mm, inner diameter 0.125mm)
with 2.5mm protrusion below the end of the guide cannula
to reach the target region. PACAP was diluted in sterile aCSF
containing 0.05% bovine serum albumin (Sigma Chemicals,
St. Louis, Mo, USA) and administered at a dose of 50 or
100pmol into CeA in a volume of 0.2 µL over a 30-second
period. The internal cannula remained inserted for 1 minute
post injection to prevent backﬂow and to allow for diﬀusion
ofthepeptide.TheinternalcannulawasthenwithdrawnandGabor Legradi et al. 3
the animal was placed immediately into the shock-probe fear
test chamber.
The shock-probe fear test apparatus consisted of a 46.6×
28 × 26 cm Plexiglas chamber, evenly covered with 5cm of
Tek-fresh odor-absorbent bedding material (Harlan Teklad,
Madison, Wis, USA). The shock-probe (8cm long and
0.8cm in diameter) was inserted through a hole on one
wall of the chamber, 2cm above the bedding material and
helically wrapped with two copper wires through which
electric current could be administered. The probe was not
electriﬁed until the spontaneously moving rat touched it
with its forepaws, at which point the animal received a
brief, 2mA shock from the shock source (precision ani-
mal shocker, model H13-15, Coulbourn Instruments, Allen-
town, Pa, USA), remotely activated by an investigator using a
footswitch.The20-minutetestbeganoncetheratreceivedits
ﬁrstshockandtheproberemainedelectriﬁedfortheremain-
der of this period. To determine whether intra-CeA infusion
of PACAP, without shocks, would produce alterations in be-
haviors, a group of rats was subjected to intra-CeA aCSF or
PACAP injections and 20-minute exposure to the test cham-
ber in the presence of an unelectriﬁed probe. Animal behav-
ior in the test chamber was recorded onto digital video tape
and then saved as MPEG2 digital video ﬁles for subsequent
observation, scoring, and automated analysis.
2.3. Veriﬁcationofinjectionsites
Immediately after behavioral testing, animals were deeply
anesthetized with Nembutal (90mg/kg, ip) and perfused
transcardially with heparinized saline followed by a solution
containing 2% paraformaldehyde and 2.5% acrolein in .1M
phosphate buﬀer. Standard Nissl staining by cresyl violet and
immunolabeling for PACAP were used to evaluate the in-
jection sites. Tissue preparation for immunohistochemistry
was performed according to a previously described method
( N o r r h o l me ta l .[ 9]). Free ﬂoating coronal sections of the
forebrain, taken at 30 µm thickness were pretreated with
1% sodium borohydride in distilled water followed by .5%
hydrogen peroxide in phosphate-buﬀered saline and then
preincubated in 10% normal horse serum. Sections were
incubated for 3 days at 4◦C in rabbit anti-PACAP serum
(Peninsula Laboratories Inc., San Carlos, Calif, USA) diluted
at1:10,000followedbysequentialincubationsinbiotinylated
donkey anti-rabbit IgG (1:200, Vector, Burlingame, Calif,
USA) and the ABC elite kit (1:100, Vector, Burlingame, Calif,
USA). Immunoreactivity was visualized with diaminobenzi-
dine (DAB) as chromogen. A total of ﬁfteen animals with
missed cannula placements were excluded from statistical
analysis. Ten additional animals were excluded for other
problems such as bleeding, necrosis, or inadequate spread of
synthetic PACAP immunoreactivity.
2.4. Analysisofbehaviors
The following behaviors were analyzed from digital video
ﬁles either by the automated tracking capabilities of Etho-
vision or counted using the behavior tracker (version 1.5,
www.behaviortracker.com), an event-recorder software: (a)
locomotion parameters: locomotion distance, deﬁned as the
total distance moved in the arena during the test period and
mean velocity of locomotion, (b) probe exploration, includ-
ingastretched/attend-likepostureorientedtowardtheprobe
or directly touching or sniﬃng the probe, (c) immobility, de-
ﬁned as crouching, sitting, or standing still on at least three
feet, with the body motionless except for small and slow, lat-
eral scanning movements of the head, (d) zonal preference,
deﬁned as time spent in the zone either away from the probe
or near the probe, generated by dividing the length of the test
chamber into two equal halves, (e) burying parameters: la-
tency to bury, deﬁned as the time between the ﬁrst shock and
theﬁrstburyingevent,durationoftimespentonburyingthe
probe such as spraying bedding materials toward or over the
probe,thefrequencyofburyingeventsandtheheightofbed-
ding material over the probe at the end of session, (f) num-
bers of contact-induced shocks, (g) rearing time and num-
bers of rearing events, (h) grooming time and numbers of
grooming events. The rats’ reactivity to shock was scored ac-
cording to a four-point scale (Pesold and Treit [30]) where
“1” is head or forepaw ﬂinch only, “2” is whole body ﬂinch
and/orwalkingawayfromtheprobe,“3”iswholebodyﬂinch
and running from the probe, and “4” is whole body ﬂinch
and jumping (all four paws in the air), followed by running
to the opposite end of the chamber (Pesold and Treit [30];
Treit and Pinel [23]). Mean shock reactivity scores were cal-
culated for each rat by summing the shock reactivity scores
and dividing them by the total number of shocks received.
A l ld a t aw e r ee x p r e s s e da sm e a n s± SEM and analyzed
by ANOVA, followed by post hoc analysis using the student-
newman-keuls multiple comparisons test (SigmaStat 3.0,
SPSS Inc., Chicago, Ill, USA). A probability level of P<. 05
was considered to be statistically signiﬁcant.
3. RESULTS
Asindicatorsofbaselinebehavior,measuresofexplorationof
theunelectriﬁedprobewereevaluatedfromrecordingsmade
during pretest sessions (last habituation session 24 hours be-
foretestday,asdescribedinSection 2).Nostatisticallysignif-
icantdiﬀerenceswerefoundinnumbersofprobeexploration
events and total time spent on probe exploration among sets
of rats prior to their placement into the various treatment
groups (P = .911 and P = .854, resp.).
Figure 1 demonstrates typical injection sites at the level
of the CeA using PACAP immunolabeling. The spread of the
injected synthetic peptide was veriﬁed by the presence of a
dense immunoreaction product in addition to the normal
appearanceofendogenousPACAPnerveﬁbers(Figure 1(b)).
3.1. Effectsofintra-CeAPACAPmicroinjectionon
probeexplorationandzonalpreference
andlocomotionparametersintherat
shock-probefeartest
One-way ANOVA indicated that PACAP infusion into the
CeA signiﬁcantly decreased the frequency [F(1,9) = 11.05;4 Neural Plasticity
CeL
CeM
BLA
(a) (b)
Figure 1: Histological veriﬁcation of an injection site produced by microinjected synthetic PACAP. (a) Section from control brain, injected
with aCSF vehicle. (b) Injected synthetic PACAP (50pmol) immunoreactivity in the CeA. BLA = basolateral nucleus of the amygdala, CeM
= central nucleus of the amygdala medial part, CeL = central nucleus of the amygdala, lateral part. Note the presence of high density of
endogenous PACAP ﬁbers in both (a) and (b). Arrows indicate the location of cannula track. In (b), synthetic PACAP injection is visible as
an intense dark reaction product. Scale bar = 200µm.
P = .001] and the duration of probe exploration [F(1,4) =
8.15, P<. 05)] in shocked animals (Figures 2(a), 2(b)).
A signiﬁcant main eﬀect was also found on zonal prefer-
ence by intra-CeA PACAP microinjection [near zone time;
F(4,4) = 6.49, P<. 05), away zone time; (F(4,4) = 6.52,
P<. 05)] in rats tested with the electriﬁed shock probe (Fig-
ures 2(c), 2(d)).
In addition, both total distance moved [F(4,5) = 11.46,
P<. 001] and movement velocity [F(3,5) = 13.11, P<. 001]
were signiﬁcantly reduced by intra-CeA PACAP injection in
shocked groups during the 20-minute test session (Figures
3(a), 3(b)). Immobility behavior was found only in shocked
groups, following probe contact-induced shocks. Both the
number of immobility events [F(7,5) = 10.49, P = .001]
and total time spent on immobility behavior [F(99,2) =
226.29, P<. 001] were signiﬁcantly increased by intra-CeA
PACAP-injection relative to aCSF-injected controls (Figures
3(c), 3(d)).
3.2. Burying-relatedbehaviors
One-wayANOVAindicatedasigniﬁcantmaineﬀectofintra-
CeA PACAP infusion on bury latency [F(4,4) = 6.55, P<
.05], total duration of burying [F(1,7) = 13.17; P<. 001],
bury events [F(1,5) = 16.56, P<. 001], and the height
of bedding over the probe [F(2,3) = 31.52, P<. 001] as
compared to aCSF controls. Probe burying was signiﬁcantly
delayed in PACAP-injected rats compared to aCSF controls
(Figure 4(a)). Intra-CeA PACAP-injected rats displayed sig-
niﬁcantly reduced number of burying events (Figure 4(b)).
The total amount of time spent on burying the electriﬁed
shock probe was also signiﬁcantly decreased by PACAP in-
jection as compared to aCSF controls (Figure 4(c)). As a re-
sult, the height of the bedding material over the probe at the
end of the test session was signiﬁcantly reduced in both the
50 and 100pmol PACAP-injected groups (Figure 4(d)).
3.3. Intra-CeAPACAPinfusionreducesnumberof
shockswithoutalteringindividualshock
reactivity
Intra-CeA PACAP infusion resulted in a signiﬁcant reduc-
tion in the number of shocks received, relative to intra-CeA
aCSF-injected rats [F(5,5) = 5.12, P<. 05] (Figure 4(e)).
However, no signiﬁcant diﬀerences were found in the shock
reactivity index between aCSF and PACAP-injected groups
(Figure 4(f)).
3.4. Intra-CeAPACAPinjectiondoesnotalter
explorationoftheunelectriﬁedprobeor
locomotionparametersin
unshockedrats
No statistically signiﬁcant eﬀects were found in probe ex-
ploration in PACAP-injected unshocked groups compared to
their respective aCSF-injected controls (Figures 5(a), 5(b)).
No intra-CeA PACAP injection eﬀects were found in an-
imals tested with the unelectriﬁed shock probe as in un-
shocked groups, near and away zone times were roughly
equal, and unaltered by intra-CeA PACAP injection (Figures
5(c), 5(d)). In unshocked groups, intra-CeA PACAP injec-
tion did not produce statistically signiﬁcant diﬀerences in to-
tal distance moved movement or movement velocity com-
pared to their respective aCSF-injected control (Figures 5(e),
5(f)). No burying behavior directed speciﬁcally toward the
probe was found in unshocked groups, regardless of treat-
ment (data not shown).
3.5. Intra-CeAinfusionofPACAPdoesnotalter
groomingandrearingbehaviorsineithershocked
orunshockedconditions
PACAP microinjection into the CeA at either dose did not
signiﬁcantly alter the frequency or duration of rearing andGabor Legradi et al. 5
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Figure 2: Eﬀects of intra-CeA microinfusion of PACAP on shock-probe exploration and zonal preference in shocked rats. The numbers of
probe exploration events (a) and time spent on probe exploration (b) are signiﬁcantly reduced by intra-CeA PACAP. Zonal preference is
altered by intra-CeA PACAP microinjection as rats spent signiﬁcantly less time in the near zone (c) but more time in the zone away from the
electriﬁed shock probe (d). ∗P<. 05 and ∗∗P ≤ .001 compared to aCSF controls. (aCSF n = 7/group, PACAP50 n = 7/group, PACAP100
n = 4/group).
grooming behaviors as compared to their respective controls
(Figure 6).
4. DISCUSSION
Since PACAP’s discovery, experimental studies have identi-
ﬁed roles for PACAP as a multifunctional molecule acting
as a neurotransmitter/modulator, neurotrophic factor, sup-
plementary hypophysiotropic hormone, and peripheral va-
sodilator(Arimura[31];Vaudryetal.[32])buttheparticipa-
tion of PACAP in neural systems and behavioral functions is
inadequately understood. Since strikingly high local concen-
trations of PACAP immunopositive nerve ﬁbers are found in
the central nucleus of the amygdala (CeA) (Koves et al. [17];
Kivipelto et al. [18]; Piggins et al. [19]; Kozicz et al. [20];
Hannibal [21]), a structure associated with the expression of
aversion and fear, we hypothesized that PACAP at the level of
the CeA could modulate fear-related behaviors. The present
study investigated the eﬀects of intra-CeA PACAP microin-
jection on behavioral responses using the shock-probe fear
(defensive burying) test. In this paradigm, the animal is con-
fronted with an electriﬁed shock probe wrapped with unin-
sulated wires from which shocks are administered. When the
spontaneously moving rat touches the probe by exploration,
the resultant behavioral response whether active burying or
passive (e.g. withdrawal and immobility) can be evaluated
usingautomatedandsemiautomatedobservation.Inthetra-
ditional interpretation of the test, increased probe burying
while locomotion is unaltered indicates an anxiogenic re-
sponse, and reduced burying with increased contact induced
shock may indicate anxiolysis. On the other hand, increased
withdrawalfromtheprobeandreductionincontact-induced6 Neural Plasticity
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Figure 3: Eﬀects of intra-CeA PACAP microinjection on locomotion parameters in shocked rats. Total distance moved (a) and mean move-
ment velocity (b) were signiﬁcantly reduced by intra-CeA PACAP microinjection. Immobility events (c) and total time spent on immobility
(d) following probe-contact-induced shocks were increased by intra-CeA PACAP. ∗P<. 05 and ∗∗P ≤ .001 compared to aCSF controls.
shocks, particularly in the version of the test used by our
study where the shock source remains continuously electri-
ﬁed(TreitandFundytus[33])canalsobeinterpretedasmea-
sures of heightened innate fear. Indeed, our results indicated
that intra-CeA microinfusion of PACAP (50 or 100pmol)
enhanced certain types of aversive behaviors in the shock-
probe fear test, consistent with our notion that PACAPergic
neurotransmission may be linked to manifestations of stress
and fear (Agarwal et al. [8]; Norrholm et al. [9]).
In the current study, intra-CeA PACAP injection pro-
duced a signiﬁcant increase in the withdrawal of the shocked
ratsawayfromtheelectriﬁedprobe,resultingindramatically
reducednumbersofcontactinducedshocks.Durationofim-
mobility and time spent in the away zone were markedly el-
evated in CeA-PACAP-injected animals. Time spent in the
near zone, latency of the last shock, duration of burying,
and the height of bedding over the probe were also greatly
reduced relative to aCSF-injected animals. Measures of lo-
comotion (total distance and time) and velocity of move-
ment were reduced in intra-CeA PACAP-injected animals
tested with the electriﬁed shock probe. In the 4-point shock-
reactivity scale, (Pesold and Treit [30]; Treit and Pinel [23]),
no statistically signiﬁcant diﬀerences were found between
intra-CeA vehicle-injected and intra-CeA PACAP-injected
rats, indicating that the observed behavioral manifestations
were not overtly inﬂuenced by organismic variables such as
possible changes in shock sensation. Collectively, these data
highlight the importance of the CeA in the reorganization
of coping strategy in CeA-PACAP-injected animals using the
shock-probe fear test to elicit fear and anxiety related re-
sponses.
Thus, intra-CeA PACAP-injected animals react with a
passive behavioral coping response, which reduces the num-
bers of shocks received. The mechanisms leading to theGabor Legradi et al. 7
P
A
C
A
P
1
0
0
P
A
C
A
P
5
0
a
C
S
F 0
250
500
750
1000
T
i
m
e
(
s
)
∗
∗
(a) Bury latency
P
A
C
A
P
1
0
0
P
A
C
A
P
5
0
a
C
S
F 0
10
20
30
40
50
E
v
e
n
t
s
/
s
e
s
s
i
o
n
∗∗
∗∗
(b) Bury events
P
A
C
A
P
1
0
0
P
A
C
A
P
5
0
a
C
S
F 0
100
200
300
T
i
m
e
(
s
)
∗∗
∗∗
(c) Bury time
P
A
C
A
P
1
0
0
P
A
C
A
P
5
0
a
C
S
F 0
1
2
3
4
5
H
e
i
g
h
t
(
c
m
)
∗∗
∗∗
(d) Bedding height
P
A
C
A
P
1
0
0
P
A
C
A
P
5
0
a
C
S
F 0
2
4
6
S
h
o
c
k
s
/
s
e
s
s
i
o
n
∗ ∗
(e) Number of shocks
P
A
C
A
P
1
0
0
P
A
C
A
P
5
0
a
C
S
F 0
1
2
3
4
S
h
o
c
k
r
e
a
c
t
i
v
i
t
y
i
n
d
e
x
(f) Shock reactivity
Figure 4: Eﬀect of intra-CeA PACAP administration on shock-probe burying and shock-related behaviors. Latency to bury the electriﬁed
shock probe (a) was signiﬁcantly increased in PACAP-injected animals whereas burying events (b) and time (c) and the height of bedding
over the probe (d) were reduced. The number of probe-contact-induced shocks (e) was signiﬁcantly reduced in PACAP-injected animals but
shock reactivity (e) was unaltered. ∗P<. 05 and ∗∗P ≤ .001 compared to aCSF controls.
behavioral manifestations of PACAP-shock interactions are
not known, but we suggest that administration of PACAP
in the CeA, likely acting upon its cognate receptor which is
widely expressed in the amygdala (Hashimoto et al. [22]),
produces its pharmacologic eﬀects locally, on neurons of the
CeA. It is therefore possible that the observed pharmacologic
eﬀect of PACAP on the behaviors we have described here re-
ﬂect a role for the endogenous PACAP nerve ﬁbers in the8 Neural Plasticity
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Figure 5: Summary of relevant behaviors of rats tested with the unelectriﬁed shock probe (unshocked groups). Intra-CeA PACAP microin-
jection, in the absence of shocks, had no signiﬁcant main eﬀect on rat behaviors in the test chamber. (a) probe exploration events, (b) probe
exploration time, (c) near zone time, (d) away zone time, (e) total distance moved, and (f) movement velocity. ∗P<. 05 and ∗∗P ≤ .001
compared to aCSF controls. (aCSF n = 6/group, PACAP50 n = 4/group, PACAP100 n = 5/group.)
C e A( K o v e se ta l .[ 17]; Piggins et al. [19]; Hannibal [21])
in the formation of coping behaviors in response to strong
aversive stimulation. Determination of the exact contribu-
tion of PACAP to responses evoked from the CeA is ulti-
mately dependent on the nature of the target neurons inﬂu-
enced by this neuropeptide. Based on the high concentra-
tion of PACAP nerve ﬁbers in the lateral, capsular subnu-
clei and medium density PACAP innervation in the medialGabor Legradi et al. 9
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Figure 6: Grooming and rearing behaviors of shocked and unshocked rats in the shock-probe fear chamber. Intra-CeA PACAP microinjec-
tion had no statistically signiﬁcant eﬀects on grooming events (a) and time (b) or rearing events (c) and time (d) in shocked or unshocked
groups of rats, relative to their respective aCSF-injected controls.
subnucleus of CeA, enkephalin, neurotensin, GABA, and
CRH-containing neurons (Cassell et al. [34]) may repre-
sent natural targets of PACAP’s physiologic eﬀects. Likewise,
the behavioral pharmacologic eﬀects observed in the current
study most likely reﬂect PACAP’s actions on several classes of
CeA neurons that may be interneurons and/or output pro-
jection neurons.
It has been recognized that the CeA serves as an output
nucleus of the amygdala. Its eﬀerent ﬁbers project to the hy-
pothalamus and brainstem areas such as the periaqueductal
gray, parabrachial and caudal pontine reticular nuclei and
the nucleus of the solitary tract, which are poised to mediate
fear-related behaviors, including immobility and autonomic
responses (Hopkins and Holstege [35]; LeDoux et al. [36];
Hitchcock et al. [37]; Saha et al. [38]). Immobility is consid-
ered as a ﬁrst stage of defense when an animal is confronted
with a threat, triggering increased vigilance and immobility.
In this fear state, the organism has been primed to respond,
but is not yet active; an exaggerated startle response is typi-
cally found (Lang et al. [39]). CeA lesions block the expres-
sionofimmobilitytofearfulstimuli(LeDouxetal.[36]),and
attenuate the development of the passive emotional and au-
tonomic components of the coping response (Roozendaal et
al. [40, 41]). Activation of the CeA may be linked with the
augmentation of passive behavioral coping (Roozendaal et
al. [42]) and potentiated startle reﬂex as well as post-stress
freezing (Tinsley and Fanselow [43]).
While the cellular and molecular eﬀects of PACAP have
not been examined speciﬁcally at the level of CeA, sev-
eral lines of evidence suggest that in general, PACAP is
an excitatory neuropeptide. PACAP is known to colocal-
ize with the major excitatory transmitter glutamate in the10 Neural Plasticity
retinohypothalamic nerve ﬁbers (Hannibal et al. [44]). The
presence of PACAP in primary aﬀerent nerve ﬁbers of the
spinal and medullary dorsal horn as well as brainstem cathe-
cholamine neurons also suggests an association with excita-
tory neurotransmission (Legradi et al. [45]; Dun et al. [46];
Legradi et al. [47]; Das et al. [48]).
Interactions between PACAP and other neuropep-
tides/neurotransmitters, such as CRH, are quite likely to oc-
cur. Based on earlier reports, we hypothesize that the ef-
fects of PACAP on fear-related behaviors may be mediated
through interaction between PACAP and CRH neurons at
hypothalamic, as well as extrahypothalamic, sites (Kozicz et
al. [20]; Agarwal et al. [8]). Psychological stress induces CRH
gene expression in the amygdala (Makino et al. [49]), antag-
onism of CRH receptors in the CeA reduces freezing induced
by foot shocks (Diamant et al. [50]) and icv CRH adminis-
tration promotes freezing and reduces shock-probe burying
(Swiergiel et al. [51]). Thus, the central action of CRH medi-
ated in part at the level of the CeA is to enhance passive emo-
tional coping. In this context, PACAP in the CeA appears to
mimic actions of CRH. Perhaps CRH is an immediate down-
stream target of PACAP’s action in the CeA. If this were the
case,thencoadministration ofaCRHantagonist andPACAP
should abolish or signiﬁcantly blunt the eﬀects of PACAP on
fear-related behaviors.
The action of PACAP on the CeA and the resultant re-
organization of behavior towards a passive, rather than an
active, stress-coping mechanism, is perhaps responsible for
shifting of the balance between competing active/passive-
coping strategies, regulated by the interplay between various
centers of the brain. It is possible that the normally occur-
ring active shock-probe burying response is related to the
functionofthemedialprefrontalcortex(mPFC),akeystruc-
ture in the organization of goal-oriented behaviors (Haddon
and Killcross [52]). The presumed PACAP-induced increase
in the activity of the CeA may override the inﬂuence of the
mPFC (decision-making) process, in favor of the more in-
stinctual immobility responses to shock. In support of this
speculation are the ﬁndings that mPFC stimulation inhibits
C e Ao u t p u tn e u r o n s( Q u i r ke ta l .[ 53]), and that excitotoxic
lesions of the mPFC or its pharmacologic inactivation with
muscimol potently inhibit fear, speciﬁcally reducing active
stress coping such as shock-probe burying (Shah and Treit
[54]; Shah et al. [55]).
It is important to further note that PACAP injection
alone, in the presence of an unelectriﬁed probe, did not have
an eﬀect on measures of locomotion, immobility, frequency,
and duration of probe exploration and zonal preference
as compared to the corresponding aCSF- injected controls.
Thus,thepotentiation offear-relatedbehaviorsbyintra-CeA
PACAP injection occurred only in shocked rats. This ﬁnding
provides strong support for the notion that PACAP is active
in modifying CeA functions only when the animal is chal-
lenged by an aversive stimulus.
In summary, the present study reveals substantial eﬀects
of PACAP microinjection into the CeA on the expression of
behavioral coping strategies in response to a fear-provoking
stimulus. In the shock-probe fear test (defensive burying
paradigm), intra-CeA PACAP at 50 or 100pmol doses in-
duced a remarkable shift from active (burying) to passive
(withdrawal) coping strategies. Infusion of PACAP into CeA
resulted in no speciﬁc alterations in locomotion or probe ex-
ploration responses when animals were tested with an un-
electriﬁed probe, indicating that PACAP’s eﬀects were mani-
fested only when the animal was challenged by aversive stim-
uli (shock). Thus, in addition to delineating the PACAPergic
modulation of amygdala physiology and the neurobiology of
fear, these studies may also have important implications to-
ward understanding the role of PACAP in the neural basis of
anxiety disorders.
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